Search Results - "Fautrel, B"

Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies by Salmon, J.H, Rat, A.C, Sellam, J, Michel, M, Eschard, J.P, Guillemin, F, Jolly, D, Fautrel, B

“…Abstract Objective An overview of the economic consequences – overall costs as well as cost breakdown (direct and indirect) – of hip and knee osteoarthritis…”
Get full text

Health resource use and costs of symptomatic knee and/or hip osteoarthritis by Salmon, J.H., Rat, A.C., Achit, H., Ngueyon-Sime, W., Gard, C., Guillemin, F., Jolly, D., Fautrel, B.

“…Data on the economic consequences of hip and knee osteoarthritis (OA) are scarce. We aimed to estimate the annual direct and indirect costs for patients…”
Get full text

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry by Salmon-Ceron, D, Tubach, F, Lortholary, O, Chosidow, O, Bretagne, S, Nicolas, N, Cuillerier, E, Fautrel, B, Michelet, C, Morel, J, Puéchal, X, Wendling, D, Lemann, M, Ravaud, P, Mariette, X

“…Anti-tumour necrosis factor (TNF) therapy may be associated with opportunistic infections (OIs). To describe the spectrum of non-tuberculosis OIs associated…”
Get more information

Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts by van Nies, J A B, Tsonaka, R, Gaujoux-Viala, C, Fautrel, B, van der Helm-van Mil, A H M

“…A prolonged symptom or disease duration at treatment initiation is associated with unfavourable outcomes in rheumatoid arthritis (RA). It is unknown whether…”
Get more information

Economic benefits of optimizing anchor therapy for rheumatoid arthritis by Fautrel, Bruno

“…The total cost of RA is substantial, particularly in patients with high levels of disability. There are considerable differences in cost between countries,…”
Get full text

Prevalence of symptomatic hip and knee osteoarthritis: a two-phase population-based survey1 by Guillemin, F., Rat, A.C., Mazieres, B., Pouchot, J., Fautrel, B., Euller-Ziegler, L., Fardellone, P., Morvan, J., Roux, C.H., Verrouil, E., Saraux, A., Coste, J.

Get full text

Development and validation of the Flare-OA questionnaire for measuring flare in knee and hip osteoarthritis by Traore, Y., Epstein, J., Spitz, E., March, L., Maillefert, J.-F., Rutherford, C., Ricatte, C., Alleyrat, C., Cross, M., King, L.K., Callahan, L.F., Fautrel, B., Buttel, T., Hawker, G., Hunter, D.J., Guillemin, F.

“…Ability to assess flares in osteoarthritis (OA) of the knee and hip (KHOA) is important in clinical care and research. Using mixed methods, we developed a…”
Get full text

Prevalence of symptomatic hip and knee osteoarthritis: a two-phase population-based survey by Guillemin, F, Rat, A.C, Mazieres, B, Pouchot, J, Fautrel, B, Euller-Ziegler, L, Fardellone, P, Morvan, J, Roux, C.H, Verrouil, E, Saraux, A, Coste, J

“…Summary Objective Osteoarthritis (OA) epidemiologic data are scarce in Europe. To estimate the prevalence of symptomatic knee and hip OA in a multiregional…”
Get full text

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France by Lequerré, T, Quartier, P, Rosellini, D, Alaoui, F, De Bandt, M, Mejjad, O, Kone-Paut, I, Michel, M, Dernis, E, Khellaf, M, Limal, N, Job-Deslandre, C, Fautrel, B, Le Loët, X, Sibilia, J

“…Anakinra treatment has been reported to be effective in some patients with systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease…”
Get more information

Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study by Gardette, A., Ottaviani, S., Sellam, J., Berenbaum, F., Lioté, F., Meyer, A., Sibilia, J., Fautrel, B., Palazzo, E., Dieudé, P.

“…Several studies have suggested that obesity could have a negative effect on response to anti-tumor necrosis factor α (anti-TNFα) in rheumatoid arthritis (RA)…”
Get full text

Tumour necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases by Fautrel, B, Sibilia, J, Mariette, X, Combe, B

“…Background: Consensus is lacking on treatment for corticosteroid resistant adult onset Still’s disease (ASD). Objective: To assess anti-TNFα efficacy and…”
Get full text

The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA) by Barroso, N., Woodworth, T. G., Furst, D. E., Guillemin, F., Fautrel, B. J., Borazan, N., Kafaja, S., Brook, J., Elashoff, D. A., Ranganath, V. K.

“…Objective To evaluate use of a British English version of the validated French FLARE-RA questionnaire among American English speaking patients. In addition, to…”
Get full text

Bone marrow oedema predicts structural progression in a 1-year follow-up of 85 patients with RA in remission or with low disease activity with low-field MRI by Gandjbakhch, F, Foltz, V, Mallet, A, Bourgeois, P, Fautrel, B

“…To identify the predictive factors of MRI-determined structural progression in patients with rheumatoid arthritis (RA) in remission or with low disease…”
Get more information

Predictors of fatigue and persistent fatigue in early rheumatoid arthritis: a longitudinal observational study, data from the ESPOIR cohort by Rodríguez-Muguruza, S, Combe, B, Guillemin, F, Fautrel, B, Olive, A, Marsal, S, Valero, O, Rincheval, N, Lukas, C

“…To determine, in a cohort of patients with early rheumatoid arthritis (RA), factors associated with fatigue at baseline, describe its evolution over 5 years of…”
Get full text

Tumour necrosis factor   blocking agents in refractory adult Still's disease: an observational study of 20 cases by Fautrel, B

“…Background: Consensus is lacking on treatment for corticosteroid resistant adult onset Still's disease (ASD). Objective: To assess anti-TNFα efficacy and…”
Get full text

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison by Fautrel, B, Zhu, B, Taylor, P C, van de Laar, M, Emery, P, De Leonardis, F, Kannowski, C L, Nicolay, C, Kadziola, Z, De La Torre, I, Fleischmann, R

“…ObjectiveTo compare improvement in pain and physical function for patients treated with baricitinib, adalimumab, tocilizumab and tofacitinib monotherapy from…”
Get full text

Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature by LEVY, L, FAUTREL, B, BARNETCHE, T, SCHAEVERBEKE, T

“…There is substantial evidence of excess cardiovascular morbidity and mortality in rheumatoid arthritis (RA) patients, but the related studies showed important…”
Get full text

Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort by Soubrier, M, Lukas, C, Sibilia, J, Fautrel, B, Roux, F, Gossec, L, Patternotte, S, Dougados, M

“…To compare the efficacy of disease activity score in 28 joints (DAS28ESR)-driven therapy with anti-tumour necrosis factor (patients from the GUEPARD trial) and…”
Get more information

Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data by Fautrel, Bruno, Combe, B, Rincheval, N, Dougados, M

“…In 2010, new classification criteria for rheumatoid arthritis (RA) were developed. To assess agreement between 1987 American College of Rheumatology (ACR) and…”
Get more information

AA amyloidosis secondary to adult onset Still's disease: About 19 cases by Delplanque, M., Pouchot, J., Ducharme-Bénard, S., Fautrel, B.J, Benyamine, A., Daniel, L., Gendre, T., Grateau, G., Georgin-Lavialle, S.

“…Adult onset Still's disease (AOSD) is an inflammatory disorder characterized by high spiking fever, evanescent rash, polyarthritis, and many other systemic…”
Get full text